Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 25;16:531–540. doi: 10.2147/OPTH.S345403

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Takahashi et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Outcomes after 12 months of treatment: (A) VA stratified by disease type; (B) VA stratified by disease type (typical AMD) and treatment modality; (C) VA stratified by disease type (PCV) and treatment modality; (D) CRT stratified by disease type; (E) CRT stratified by disease type (PCV) and treatment modality; (F) Number of anti-VEGF injections stratified by disease type; and (G) Number of anti-VEGF injections stratified by disease type (PCV) and treatment modality; baseline values vary by treatment group.

Abbreviations: AMD, age-related macular degeneration; CRT, central retinal thickness; logMAR, logarithm of the minimum angle of resolution; PCV, polypoidal choroidal vasculopathy; PDT, photodynamic therapy; VA, visual acuity; VEGF, vascular endothelial growth factor.